


# 2006 ANNUAL REPORT

Improving the quality of life for animals and people






## Table of contents

	<b>About IFAH-Europe</b> .....	<b>5</b>
	<b>A message from IFAH-Europe's Chairman and Managing Director</b> ..	<b>6</b>
	<b>Activities and achievements in 2006</b> .....	<b>8</b>
	Regulatory affairs .....	8
	Food chain issues .....	11
	Communications .....	12
	<b>Striving to improve control of animal diseases</b> .....	<b>14</b>
	<b>Seeking alternatives to animal testing</b> .....	<b>15</b>
	<b>Future challenges</b> .....	<b>16</b>
	Regulatory affairs .....	16
	Food chain issues .....	17
	Communications .....	18
	<b>The European animal health industry in profile</b> .....	<b>19</b>
	<b>IFAH-Europe membership</b> .....	<b>20</b>
	<b>IFAH-Europe secretariat</b> .....	<b>25</b>
	<b>Glossary</b> .....	<b>26</b>





## About IFAH-Europe

IFAH-Europe is the federation representing manufacturers of veterinary medicines, vaccines and other animal health products in Europe. It represents both corporate members and national animal health associations across the region. These associations comprise local, regional and international companies. IFAH-Europe's membership covers 95% of the European market for veterinary products.

## IFAH-Europe's mission

IFAH-Europe's mission is to promote a predictable, harmonised, science-based and innovative market place for the provision of quality animal medicines, vaccines and other animal health products, and so contribute to a healthy and safe food supply and to high standards of health and welfare for animals and people.

As a responsible industry we want to ensure that our stakeholders understand the work we do and the wide range of benefits we give to society at large. To achieve this, IFAH-Europe, as the voice of the European animal health industry, encourages constructive dialogue with governments, public policy makers, legislators, regulators, non-governmental organisations, the veterinary profession, the food chain, consumers and other stakeholders.

# A message from IFAH-Europe's Chairman and Managing Director

Animal health, animal welfare, food safety and public health: four key issues - all of them inextricably linked - that have occupied the minds of consumers, politicians and regulators to a growing extent in recent years. And four key goals that are effectively the *raison d'être* of our industry.

With many stakeholders sharing so many fundamental objectives, cooperation makes perfect sense. This basic truth is something that IFAH-Europe has always recognised, and the federation has worked tirelessly to build relationships that span the many sectors involved in protecting the health of food-producing and companion animals and the production of safe, high quality food.

The year started off with IFAH-Europe addressing a meeting of the Scientific Committee for the Food Chain and Animal Health (SCFCAH) on the subject of highly pathogenic avian influenza (HPAI). The 27 Member States were represented along with Croatia, Iceland, Macedonia, Norway and Ukraine. Our message was that the industry has products to protect poultry from HPAI that may be used as a tool in the context of preventative measures and stamping out. Later in the year, considerable progress was made in the licensing process and a number of products received licenses for use across all Member States.

IFAH-Europe has emerged as a driving force behind the European Platform for the Responsible Use of Medicines in Animals (EPRUMA) initiative, which aims to promote the responsible use of animal medicines in Europe, and is a founder member of multi-stakeholder initiatives designed variously to improve animal welfare, promote food safety and enhance research into the prevention, treatment and control of animal disease. Its co-operative message was summed up appropriately in the title of our 2006 annual conference: *'The animal health industry - an essential partner for global health'*, which showcased the crucial role played by veterinary medicines.

Looking back on 2006, we were very pleased with the success of our flagship conference, but also with real progress we made towards achieving a range of other goals. While it would be impossible to list those achievements in full here, we should make special mention of the work put in by our Communications and Food Chain committees, ably supported by our secretariat, which did so much to drive forward initiatives such as EPRUMA, and to heighten awareness of the positive role played by our industry.

Progress reported with the European Technology Platform for Global Animal Health (ETPGAH) is also worthy of note. Alongside its fellow stakeholders in this newly formed alliance, the federation unveiled a strategic research agenda (SRA) that promises to improve collaboration and boost rates of innovation in the animal health sector, helping to deliver new tools for the prevention, treatment and control of animal disease in future.

The calls for research published by DG Research in late December included many addressing the recommendations in the strategic research agenda. This represents substantive progress in delivering the SRA. It also confirms that the work of the ETPGAH is being taken very seriously by the various parties deciding on the prioritisation of funding within the European Research Framework.

If we are to continue delivering high quality, innovative new products, it is essential that our industry is governed by an efficient, proportionate regulatory framework. Our Technical and Regulatory Committee, together with its specialist working parties and ad hoc groups, has already done much to secure improvements in the EU regulatory framework. Those efforts will now be stepped up, however, as we press for further changes in the regulatory sphere.

Throughout the coming year, IFAH-Europe will use the results of its recent benchmarking survey to drive home the need to reform regulations in several key areas, which our research shows continues to impose a disproportionate burden on the animal health industry. We are confident that the strength of our arguments, combined with the mutual trust that we have built with regulators over the years, will pave the way for further success.

Importantly, we contributed to the development of the Community Animal Health Policy (CAHP) establishing a high-level policy approach to a range of animal health issues. We are very pleased that the CAHP recognises the important role that the ETPGAH and innovation in animal health will play into the future.

The past year was also notable in terms of IFAH-Europe's representation. The federation welcomed national associations representing the industry in both Finland and Sweden as new members, and added Huvepharma to its list of corporate members. We trust that they will all enjoy the considerable benefits resulting from membership, and are sure that IFAH-Europe in turn will be strengthened further by their inclusion.

Finally, we would like to acknowledge the outstanding work put in by colleagues from member companies, associations and our dedicated secretariat over the past year. It is thanks to those efforts that we are able to describe such positive progress in this report, and that we are confident 2007 will be another successful year for IFAH-Europe.



Brian Clark  
Chairman



Declan O'Brien  
Managing Director

# Activities and achievements in 2006

IFAH-Europe focuses its resources on three strategic areas:

- Regulatory affairs
- Food chain issues
- Communications

## Regulatory affairs

Discovering, developing and bringing to market innovative new medicines requires substantial levels of investment. IFAH-Europe actively promotes the rigorous, science-based regulation of veterinary medicines, which is essential to guarantee the protection of animal and human health. Equally, if it is to encourage continued investment in the development of new products, the regulatory framework must be proportionate, predictable and efficient. Improving the efficiency of regulatory procedures and ensuring that vets and animal owners have access to a broad range of products for the treatment and prevention of disease are key goals of IFAH-Europe's activities in regulatory affairs.

Tracking developments in the regulatory framework governing animal health products in the EU, responding to consultation documents and developing industry position papers on key issues is a considerable task. This work is channelled through a total of eleven working groups, each focused on specific technical or regulatory issues and all reporting to the federation's Technical and

Regulatory Committee. Staffed by a total of 205 experts drawn from member companies and associations, they held 39 meetings, reviewed and prepared responses to over 40 consultation documents and debated, drafted or finalised more than 50 project-related documents in the course of 2006. Regulatory and technical representatives also participated in 77 external meetings and conferences during the year.

### **Improving the regulatory framework:**

New legislation governing veterinary medicinal products in the EU came into force in November 2005, and 2006 saw the introduction of several implementing measures, including prescription-only exemption criteria, a guideline on the definition of 'serious risk' and the introduction of new pharmacovigilance requirements. Using feedback on early experience with the new framework, IFAH-Europe established a project designed to assess the impact of the legislation on innovation. Along with a broader benchmarking study undertaken by the federation, results will be used to support calls for further improvement of the regulatory framework, in terms of both its efficiency and the impact of existing rules on the cost and time involved in bringing new veterinary medicines to market.

Separately, testing and data requirements in support of marketing authorisations (MAs) contained in Annex I of Directive 2001/82, and regulations governing variations to the terms of existing MAs are already being reviewed. IFAH-Europe has devoted considerable resources to both of these issues, responding to consultations, developing position papers and submitting detailed proposals for changes to existing legislation. It will continue to monitor developments closely in 2007, and is optimistic that significant improvements will eventually be forthcoming as a result of its work - particularly where legislation governing variations is concerned.





Removing and preventing the introduction of disproportionate regulatory demands has potentially major implications for IFAH-Europe's member companies, and is the goal of other key projects. The federation was involved in detailed negotiations throughout 2006 on the implementation of amended official vaccine batch testing procedures and the extension of good manufacturing practice requirements, calling in both cases for a pragmatic approach. It also developed a series of proposals aimed at removing barriers to medicines availability posed by labelling and packaging regulations, which were discussed in detail during a workshop held with the authorities. Medicines availability issues were discussed at a broader level by a Heads of Medicine Agencies (HMA) task force to which IFAH-Europe contributed.

A positive spirit of cooperation was also evident in developments with regard to the fight against avian influenza during 2006. IFAH-Europe and its members worked hard to appraise the authorities of the industry's capabilities, and were consulted in detail on the development of accelerated assessment procedures for AI vaccines, under which conditional authorisations were approved for two new products during the year.

The federation's technical and regulatory committees and working groups continued to monitor broader EU approval procedures through detailed annual surveys, which provide valuable data on ways in which these can be refined and improved. A survey of the new 'decentralised' procedure (DCP), which will play a key role in the new EU regulatory system, was initiated during 2006. Looking to the future, a new working group was established to take responsibility for the development of a discussion paper examining the practicalities of electronic submission systems.

**Defending antimicrobial use:** Securing the continued availability of antimicrobials for use in veterinary medicine, and ensuring appropriate use of these valuable products are high on IFAH-Europe's list of priorities. The federation has played an active role in the debate surrounding antibiotic resistance, has worked with regulators and fellow stakeholders to encourage prudent use of anti-infectives, and has been closely involved in the coordination of antibiotic use surveys and monitoring programmes across Europe.

IFAH-Europe is particularly concerned about approaches to the establishment of antimicrobial breakpoints (concentrations used to interpret





antibiotic susceptibility test results), which it feels do not place sufficient emphasis on clinical outcomes. The federation's persuasive arguments in favour of a harmonised, clinically-based approach were highlighted in an article published by the *Veterinary Microbiology* journal, and by an award-winning poster presentation at the 10<sup>th</sup> international congress of the European Association for Veterinary Pharmacology and Toxicology (EAVPT).

The EMEA's Committee for Medicinal Products for Veterinary Use (CVMP) published a reflection paper on the use of fluoroquinolone antibiotics in food-producing animals during 2006. Encouragingly, it concluded that most problems with resistance encountered in human medicine are correlated to human use of fluoroquinolones, and acknowledged the importance of the class to veterinary medicine. IFAH-Europe endorsed CVMP proposals, issued towards the end of the year, for the inclusion of 'prudent use' statements in product information for fluoroquinolones.

At a broader level, IFAH-Europe continued to encourage appropriate use of anti-infectives in general through its involvement in the European Partnership for Responsible Use of Medicines in Animals (EPRUMA). Alongside its partners in this alliance, the federation has developed a framework guide on best practice in the use of therapeutic antibiotics, which was greeted positively by a broad range of stakeholders attending an EPRUMA workshop held in November.

**International activities:** The Anti-Infectives Working Party also made a valuable contribution to IFAH's Global Antibiotics Core Team (GACT), supplying key data in support of a broad approach to the 'critical list' of veterinary antibiotics being drawn up by the OIE, presenting industry viewpoints at a range of external events and participating in the

GACT's 'outreach' initiative, which is designed to strengthen lines of communication with the human medical community.

IFAH-Europe was also a substantial contributor to several other initiatives being pursued at global level by the industry during 2006. Perhaps most notable was its involvement in the VICH regulatory harmonisation programme, where the federation brought several proposals for new VICH topics to the table, and where its representatives were involved in expert working groups focused variously on biologicals quality monitoring, pharmacovigilance, target-animal safety and metabolism/residue kinetics. IFAH-Europe was also active in the development of proposals designed to improve the efficiency of the VICH process.

Elsewhere, the federation made key contributions to the work of IFAH's Global Regulatory Core Team (GRCT), which is working to increase recognition among regulators of the major differences that exist between the veterinary medicines and human pharmaceutical sectors. By raising awareness of these differences, it aims to prevent the transfer of requirements for human pharmaceuticals to veterinary products without proper consideration of their applicability, relevance and impact on veterinary medicines availability.

Dialogue with regulators remained positive and constructive, with a number of key issues discussed in depth during the EMEA/IFAH-Europe 'Info Day' held in November. The session, which attracted a record attendance, provoked lively debate on issues including benefit/risk assessment, improving the regulatory framework governing animal health products, and the need to differentiate between the human and veterinary sectors when drawing up legislation and guidelines.

# Activities and achievements in 2006

## Food chain issues

IFAH-Europe and its member associations have played a prominent role in the development of stakeholder alliances, and continue to forge productive relationships with groups representing the veterinary profession, producers, processors, retailers and consumers across the region. These will promote a better understanding of the valuable role that our industry plays in the protection of animal health and welfare, food safety and human health, and will position our industry as a credible, widely-respected contributor to debates on these issues.

### **Responsible use of animal medicines:**

Joining forces with farmers' groups and the veterinary profession, IFAH-Europe established a European Platform for Responsible Use of Medicines in Animals (EPRUMA) towards the end of 2005. Its mission is to facilitate and promote a coordinated, integrated approach by all stakeholders to ensure best practice in the responsible use of animal medicines.

Throughout 2006, EPRUMA worked on the development of a best-practice framework for the use of antimicrobials in food-producing animals. The aim of the framework document is to provide guidance for farmers and veterinarians, encouraging careful and prudent use of these valuable products in order to guarantee their safety and minimise the development of resistance.

The EPRUMA initiative was introduced to a number of other stakeholders at a workshop held towards the end of the year. Participants, who included representatives from across the agri-food sector, welcomed the scheme, and discussed future topics to be addressed by the platform, including animal vaccination. In the wake of the workshop, the European Initiative for Sustainable Development in Agriculture (EISA) announced its intention to join EPRUMA.

**Product identification:** IFAH-Europe and its member companies are spearheading an industry-led initiative to upgrade and harmonise veterinary medicine identification systems. This will facilitate distributors, retailers and veterinary surgeons to comply with legal requirements where record-keeping and the use of animal health products is concerned.

The project involves the adoption of the datamatrix identification standard, allowing the identity of a product, its batch number and expiry date to be verified with a single scan. The system has received widespread acclaim among regulators, and is being adopted increasingly in other sectors, including the human pharmaceutical industry. By the end of 2006 a number of IFAH-Europe member companies had adopted the system at major manufacturing plants, and datamatrix identification will be an integral part of member company packaging by the end of 2007.

# Activities and achievements in 2006

**Food safety:** As an associate member of the European Food Safety Authority's stakeholder consultation platform, IFAH-Europe participated actively in debates on the authority's approach to risk assessment, risk communication and the identification, characterisation and monitoring of emerging food-safety risks during the year. Representatives of the federation met with EFSA officials with a view to establishing co-operative relationships in areas such as animal health and welfare and antibiotic resistance monitoring.

IFAH-Europe also submitted its views on the performance of EFSA since its establishment, as part of a consultation exercise commissioned by the authority at the beginning of the year. The federation took this opportunity to call for an increase in the level of formal stakeholder consultation, and for the establishment of procedures that would allow stakeholders to view and comment on draft EFSA opinions prior to their adoption. It also encouraged the authority to establish closer links with the European Medicines Agency.

**Communication with stakeholders:** IFAH-Europe met with representatives from a broad range of food chain stakeholder groups - including retailers and consumers - and attended a number of conferences during the year. Presentations at these events helped to disseminate core industry messages and encourage future dialogue with a growing number of organisations. The federation also participated actively in projects organised by groups such as the European Initiative for Sustainable Development in Agriculture (EISA) and the European Agri-Food Network (EAFN), and contributed to the Advisory Group for the Food Chain and Animal and Plant Health established by DG SANCO in the European Commission.

## Communications

By communicating its values and opinions to a broad external audience, IFAH-Europe aims to reinforce the industry's position as a reliable and respected source of information on animal health issues, and as a trusted partner for fellow stakeholders. Activities in this area were stepped up during 2006, with encouraging results.

**An 'essential partner':** The flagship event in IFAH-Europe's 2006 communications programme was a conference organised by the federation to showcase the industry as 'An Essential Partner for Global Health'. Held in Brussels on 28 June, the conference attracted close to 150 delegates representing a broad range of stakeholders, and featured a keynote address by Markos Kyprianou, European Commissioner for Health and Consumer Protection.

The spread of avian influenza has heightened awareness of the need for effective tools to prevent and treat animal diseases, and of the key role played by our industry in the protection of both animal and human health. Commissioner Kyprianou told delegates that, having reviewed the existing Community Animal Health Policy (CAHP), the Commission had decided to step up its activities in the animal health field.

The conference was addressed by speakers from a range of other EU institutions, international organisations, NGOs and the industry. Participants discussed the importance of innovation in animal health and its impact on global health. They also stressed the benefits that animal health products offer to society.



**New communication tools:** IFAH-Europe strengthened its range of communication tools in 2006, launching an external newsletter, *IFAH-Europe Perspectives*, which offers readers an insight into the aims and activities of the organisation. It also contains a digest of animal health-related news from across the region. Four issues of the electronic newsletter were published during the year, with positive feedback received from a variety of readers.

An informative leaflet on veterinary vaccines was also added to a growing line of external communication materials. This new publication outlines the importance of veterinary vaccines, explains how they are developed and produced, and examines the role they play in securing the health and welfare of animals and the protection of public health. It is a short version of the federation's detailed vaccine dossier.

**Dialogue with fellow stakeholders:** As well as playing a prominent role in the development of multiple-stakeholder initiatives, IFAH-Europe held a succession of meetings with partner organisations during the year. These included discussions with the EU institutions, veterinarians, farmers, major retailers and retail-trade representatives during which the federation outlined a number of topics and initiatives, including EPRUMA. Responses were positive, with retailers welcoming the responsible use platform as a proactive measure with the potential to exert a positive impact on the food chain.

Constructive dialogue was also reported in meetings with consumer group representatives, while IFAH-Europe delegates also communicated on a regular basis with policy-makers and regulators. The federation outlined the role that vaccination can play in an integrated approach to the control of avian influenza during a meeting of the European Parliament's group on the welfare and conservation of animals.



# Striving to improve control of animal diseases

IFAH-Europe chairs a broad coalition of stakeholders that is working to improve animal health research under the umbrella of the European Technology Platform for Global Animal Health (ETPGAH). Established in 2005, the platform is designed to promote improved levels of collaboration between the public and private sectors, and to boost rates of innovation by identifying research priorities and coordinating work on the development of new tools for the prevention and treatment of animal disease.

Alongside its fellow stakeholders in this wide-ranging alliance, the federation unveiled a strategic research agenda (SRA) in the presence of Europe's Science and Research Commissioner, Janez Potočnik, in May 2006. The SRA highlights six priority areas that must be addressed if the ETPGAH is to meet its goals. These include improved funding for animal sciences, streamlining technology transfer systems and adjustment of the regulatory framework governing animal health products. The agenda also highlights the need to prioritise animal diseases, to identify gaps in product availability and research activity, and to develop alliances at international level.

Based on the strategic research agenda, four groups comprising representatives from the ETPGAH's stakeholders have been established to identify priority research areas. These will form the basis of an action plan that will see funds channelled into appropriate research fields, and will promote the most efficient possible use of

public and private sector research capabilities in the drive to develop innovative new tools for the control of animal disease.

The current focus of the ETPGAH is the development of vaccines, pharmaceuticals and diagnostic tests for use in the prevention, diagnosis and treatment of major animal diseases. By increasing funds available to researchers in the sector and ensuring that these are used efficiently, the platform aims to improve animal health and welfare, food safety and quality, and human health.



May 2006 - ETPGAH representatives presenting the SRA to Commissioner Potočnik who received it on behalf of the College of Commissioners.

# Seeking alternatives to animal testing

IFAH-Europe and its members are firmly committed to minimising the use of animals in the research and development of veterinary medicines – particularly in tests required by regulators to establish the quality, safety and efficacy of animal health products. That commitment was underlined in 2005, when the federation became a founding member of the European Partnership for Alternative Approaches to Animal Testing (EPAA), an unprecedented collaboration involving the European Commission and major companies from seven industrial sectors.

The number of animals used in tests that are required by law to confirm the safety of substances such as detergents, cosmetics, pesticides, veterinary medicines and human medicines, has already declined significantly. Regulators and manufacturers alike want to see further, major reductions in animal testing, however. The EPAA provides a unique forum within which partners can share information on how best to minimise the need for animal testing, and where new approaches to regulation can be developed, paving the way for further reductions in *in vivo* testing.

Partners in the EPAA initiative have agreed a set of principles known as the 3Rs Declaration, which encapsulate their desire to *refine, reduce and replace* the use of animals in product testing wherever possible. In 2006, the EPAA adopted an action programme outlining short, medium and long-term goals in five key areas. Prominent among these are the prioritisation, promotion and implementation of research approaches based on the application of the 3Rs, sharing of best practice, the implementation of 3R-principles into regulations and decision-making processes, and the validation and acceptance of alternative testing methods.

Working groups have been established in each of these five areas, and all reported significant progress at a conference held by the EPAA in Brussels towards the end of the year. IFAH-Europe has already developed proposals in a number of areas – including batch testing of veterinary vaccines – where it believes existing regulations can be amended, reducing the need for animal testing whilst maintaining strict controls on the safety, quality and efficacy of products.



# Future challenges

## Regulatory affairs

Improving the efficiency of the regulatory framework governing animal health products will remain a priority for IFAH-Europe, working with the European Commission within the framework of its Better Regulation initiative, and with national agencies on their strategy for an efficient European Medicines Regulatory Network. Results of the industry benchmarking study undertaken in 2006 will be discussed with European regulators at an early stage, and will be debated in detail at the federation's June conference, *Veterinary medicines regulation - is Europe still at the cutting edge of innovation?*

Key findings of the benchmarking study will be outlined in an initial session at the conference before IFAH-Europe presents its proposals for reform of the existing regulatory framework. Delegates will then have the opportunity to discuss individual issues in more detail during afternoon working group sessions. Key areas where the federation believes reform of existing regulations is essential include:

- Intellectual property and data protection
- Packaging requirements
- Level-playing field with regard to new safety data requirements and the European Reference Product procedure
- Variation procedures and costs of product maintenance



Disproportionate data requirements and the unpredictable nature of regulatory decision-making procedures continue to drive up both the costs involved in the development of new animal health products and the time it takes to bring them to market. The relative absence of incentives for the industry to invest in the extension of products to additional indications and species, as well as the development of products for minor uses or minor species, must also be addressed if existing problems with medicines availability are to be tackled successfully.

IFAH-Europe will call on regulators to harmonise and reduce existing test requirements, and to reform procedures for the development of new requirements, ensuring that future guidelines are both proportionate and risk-based.

Animal welfare is a key goal of the European Technology Platform for Global Animal Health (ETPGAH), through which IFAH-Europe will strive, alongside regulators and fellow stakeholders, to identify gaps in the range of products currently available for use in the prevention, treatment or control of animal disease. The federation will also continue to work alongside the European Commission and other stakeholders in the EPAA initiative, which aims to reduce the need for animal testing to support the development and registration of new products.





## Food chain issues

IFAH-Europe has already emerged as a driving force in the development of multiple stakeholder initiatives. The federation will continue to pursue alliances with fellow stakeholders, and to develop positive relationships with new partners in the food chain. Activities in 2007 will focus on four key issues:

- Food safety
- Animal welfare
- Responsible use of animal medicines
- Innovative animal health products

The federation is also keen to strengthen its relations with the European Food Safety Authority (EFSA), and will pursue further stakeholder involvement with the body in 2007. The EFSA has already requested IFAH-Europe's help with the provision of information on vaccines against avian influenza and a number of other important animal diseases, and the federation looks forward to further collaboration with the authority.

IFAH-Europe will lead efforts to build on the excellent progress achieved in 2006 by the EPRUMA initiative, which is designed to encourage the responsible use of animal medicines. A second EPRUMA workshop is planned following the positive outcome of the initial event held in November 2006, and the scheme will be broadened in terms of stakeholder involvement. The federation will aim in particular to engage more closely with retailers and consumers.

The 'best-practice framework' for the use of antimicrobials in food-producing animals will be developed further. Other stakeholders have already expressed support for the development of similar framework documents in other key areas such as vaccination.

# Future challenges



## Communications

Activities in the communications sphere will be focused on supporting regulatory and food chain committee initiatives, strengthening existing contacts with regulators and other key stakeholders, broadening relations with food-chain partners and working to heighten the profile of the animal health industry. Measures will also be taken to increase the flow of information about IFAH-Europe's activities to member associations and companies.

The positive role played by our industry, and its contribution to animal health and welfare, food safety and human health, will be highlighted at other external events planned for 2007 and 2008, including the latest renewal of the 'Pet Night' that has proved so successful in the past. Elsewhere, relations with fellow stakeholders will be strengthened through the federation's continued involvement in multi-sector initiatives such as EPRUMA, the ETPGAH, the EAFN and the EPAA.

The range of communication tools at the disposal of IFAH-Europe committees, working groups, member associations and companies will be further enhanced during the coming year. Plans to upgrade the IFAH-Europe website are already at an advanced stage, with changes designed to benefit members and improve the dissemination of our core messages to a broad external audience. The *Perspectives* newsletter and fact sheets on key issues will help non-specialists to learn about our industry, while new documents - including a fact sheet on innovation - are in development.

# The European animal health industry in profile




IFAH-Europe is led by a ten-member Council comprising representatives from member companies and national industry associations. Headed by IFAH-Europe chairman Brian Clark, the Council is the federation's decision-making body.

Policies agreed by the Council are executed by four key operating committees: the Technical and Regulatory Committee (TRC), the Food Chain Committee (FCC), the Committee of National

Associations (CNA) and the Communications Committee (Comcom). These are supported by a range of working parties and ad hoc groups focused on specific issues, and by a permanent secretariat led by IFAH-Europe Managing Director Declan O'Brien.

IFAH-Europe is a member of IFAH, the federation representing the animal health industry at international level.

## IFAH-Europe structure



## European sales data

Animal health products	Subtotals	Total values	%
Vaccines	€755,440,920	€755,440,920	23.4
<b>Antimicrobials</b>			
• Injectable forms:	€358,131,387		
• Oral forms:	€340,796,980	€698,928,367	21.6
<b>Parasiticides</b>			
• Endoparasiticides:	€312,977,768		
• Ectoparasiticides (ears excluded)	€443,070,123		
• Endectocides:	€118,994,818	€875,042,709	27.1
<b>Topical products (skin ecto excluded)</b>	€233,993,612	€233,993,612	7.2
<b>Other products</b>		€670,893,627	20.7
<b>Total</b>		€3,234,299,235	100.0

Europe comprises: Austria, Belgium, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Slovakia, Spain, Switzerland, the Netherlands and the United Kingdom. Source: 14 IFAH-Europe and CEESA member companies.

# IFAH-Europe membership

## IFAH-Europe Council\*

**Brian Clark** (Chairman)  
Virbac SA

**Pierre Scarcériaux** (Vice-chair)  
Janssen Animal Health

**Martin Schneidereit** (Vice-chair)  
BfT - Bundesverband für Tiergesundheit,  
Germany

**Albert Bourla** (Treasurer)  
Pfizer Animal Health

**Santiago de Andrés**  
VETERINDUSTRIA - Asociación Empresarial  
Española de la Industria de Sanidad y  
Nutrición Animal, Spain

**Jean-Louis Hunault**  
SIMV - Syndicat de l'Industrie du Médicament  
Vétérinaire et Réactif, France

**Henriette Pagh Kohl**  
VIF - Veterinærmedicinisk Industriforening,  
Denmark

**Philip Sketchley**  
NOAH - National Office of Animal Health,  
United Kingdom

**Hugo Wahnish**  
Schering-Plough Animal Health

**Jochen Wieda**  
Intervet International BV

## Corporate members\*

Alpharma Animal Health Division

Bayer HealthCare AG, Animal Health Division

Boehringer Ingelheim Animal Health

Ceva Santé Animale

Elanco Animal Health

Fort Dodge

Huvepharma NV

Intervet International BV

Janssen Animal Health

Merial Ltd

Novartis Animal Health Inc

Pfizer Animal Health

Schering-Plough Animal Health

Vétoquinol

Virbac SA

\*As at January 2007



## National association members\*

### **Belgium**

#### **Pharma.be**

(Association Générale de l'Industrie  
du Médicament)  
Veterinary Medicines Group Co-ordinator:  
Philippe van den Bossche

Chaussée de la Hulpe, 166  
B-1170 Brussels  
Belgium

Tel.: +32 2 661 9121  
Fax: + 32 2 661 9199  
pvdb@pharma.be  
www.pharma.be

### **Croatia**

#### **VETCRO**

President: Nenad Štiglic

c/o VETERINA  
Svetonedeljska 2, Kalinovica  
HR-10436 Rakov Potok  
Croatia

Tel.: +385 1 6120 999  
Fax: +385 1 6115 668  
nenad.stiglic@veterina.hr  
www.veterina.hr

### **Cyprus**

#### **CAVEMID**

(Cyprus Veterinary Medicines Importers  
and Distributors Association)  
c/o Cyprus Chamber of Commerce  
P.O. Box 21455  
1509 Nicosia  
Cyprus

Tel.: +357 22 88 97 22  
Fax: +357 22 66 86 30

Contact: Demetris Lapathiotis  
Managing Director  
c/o Agromedica Ltd

Tel.: +357 24 81 50 84  
Fax: +357 24 81 50 85

### **Denmark**

#### **VIF**

(Veterinærmedicinsk Industriforening)  
Head of Secretariat: Henriette Pagh Kohl

Strødamvej 50 A  
2100 København Ø  
Denmark

Tel.: +45 39 270 925  
Fax: +45 39 270 918  
hpk@vif.dk  
www.vif.dk

# IFAH-Europe membership



## **Finland**

### **PIF**

(Pharma Industry Finland)  
Legal Counsel: Martti Heinonen

Eteläranta 10  
P.O. box 109  
00131 Helsinki  
Finland

Tel.: +358 9 5842 4911  
Fax: +358 9 5842 4728  
martti.heinonen@pif.fi  
www.pif.fi

## **France**

### **SIMV**

(Syndicat de l'Industrie du  
Médicament Vétérinaire et Réactif)  
President: Jean-Louis Hunault

11 rue de Messageries  
75010 Paris  
France

Tel.: +33 1 5334 4343  
Fax: +33 1 5334 4344  
simv@simv.org  
www.simv.org

## **Germany**

### **BfT**

(Bundesverband für Tiergesundheit)  
Executive Director: Martin Schneiderreit

Ännchenplatz 6  
53173 Bonn Bad Godesberg  
Germany

Tel.: +49 228 318 296  
Fax: +49 228 318 298  
bft@bft-online.de  
www.bft-online.de

## **Greece**

### **HAVEPHARM**

(Hellenic Association of Distributors,  
Importers and Manufacturers of Veterinary  
Pharmaceuticals)

198 Messogion Av  
GR-155 61 Holargos  
Athens  
Greece

Tel.: +30 210 653 8061  
Fax: +30 210 653 7036

President: Stamatis Barbatiotis  
c/o Schering-Plough Veterinary SA

Tel.: +30 1 989 7432  
Fax: +30 1 988 7925  
stamatis.barbatiotis@spcorp.com

## **Italy**

### **AISA**

(Associazione Nazionale dell'Industria  
della Salute Animale)  
Executive Director: Giacomo Fortuni

Via Giovanni da Procida 11  
20149 Milan  
Italy

Tel.: +39 2 345 651  
Fax: +39 2 345 65-310  
aisa@federchimica.it  
www.aisa.federchimica.it



## **Ireland**

### **APHA**

(Animal & Plant Health Association)

Director: Brendan Barnes

8 Woodbine Park  
Blackrock  
Co Dublin  
Ireland

Tel.: +353 1 260 3050  
Fax: +353 1 260 3021  
brendan@apha.ie  
www.apha.ie

## **The Netherlands**

### **FIDIN**

(Vereniging van Fabrikanten en Importeurs van  
Diergeneesmiddelen in Nederland)

Director: Frederik Schutte

Postbus 80523  
2508 GM Den Haag  
The Netherlands

Tel.: +31 70 750 3100  
Fax: +31 70 354 9766  
fidin@fidin.nl  
www.fidin.nl

## **Poland**

### **POLPROWET**

(Polish Association of Veterinary Drug  
Producers and Importers)

President: Dr Witold Klawe

Al Jerozolimskie 158  
PL 02-326 Warszawa  
Poland

Tel.: +48 22 572 3659  
Fax: +48 22 572 3653  
klawe.witold@lilly.com

## **Portugal**

### **APIFARMA**

(Associação Portuguesa da Industria  
Farmacêutica)

Executive Director: Isabel Saraiva Cristiano

Rua Pero da Covilha 22  
1400 Lisboa  
Portugal

Tel.: +351 21 301 8264  
Fax: +351 21 301 8553  
apifarma.board@mail.telepac.pt  
www.apifarma.pt

## **Slovenia**

### **SPMA**

Working Group for Animal Health (WAH)

Director: Jože Primc

c/o

KRKA dd

Marketing and Sales Animal Health

Novo mesto  
Šmarješka cesta 6  
8501 Novo mesto  
Slovenia

Tel.: +386 7 331 2371  
Fax: +386 7 332 2631  
joze.primc@krka.biz  
www.krka.si



## **Spain**

### **VETERINDUSTRIA**

(Asociación Empresarial Española de la  
Industria de Sanidad y Nutrición Animal)  
Director General: Santiago de Andrés Juárez

San Agustín, 15-1 dcha.  
28014 Madrid  
Spain

Tel.: +34 91 369 2134  
Fax: +34 91 369 3967  
veterindustria@veter.com  
www.veterindustria.com

## **Sweden**

### **LIF**

(Läkemedelsindustriföreningen)  
Managing Veterinary Director: Pär Tellner

Ringvägen 100  
Se-118 92 Stockholm  
Sweden

Tel.: +46 8 462 3736  
Fax: +46 8 462 0292  
par.tellner@lif.se  
www.lif.se

## **Switzerland**

### **SGCI**

Chemie Pharma Schweiz  
(Swiss Society of Chemical Industries)  
Managing Director: Dieter Grauer

Nordstrasse 15  
8035 Zürich  
Switzerland

Tel.: +41 1 368 1711  
Fax: +41 1 368 1770  
dieter.grauer@sgci.ch  
www.sgci.ch

## **United Kingdom**

### **NOAH**

(National Office of Animal Health Ltd)  
Chief Executive: Philip Sketchley

3 Crossfield Chambers  
Gladbeck Way  
Enfield  
Middlesex EN2 7HF  
United Kingdom

Tel.: +44 208 367 3131  
Fax: +44 208 363 1155  
p.sketchley@noah.co.uk  
www.noah.co.uk



# IFAH-Europe secretariat

## Managing Director

### **Declan O'Brien**

Managing Director  
d.obrien@ifahsec.org

### **Florentina Pardo**

Executive Assistant  
f.pardo@ifahsec.org

## Technical Department

### **Rick Clayton**

Technical Director  
r.clayton@ifahsec.org

### **Sylvie Meillerais**

Technical Project Manager  
s.meillerais@ifahsec.org

### **Elena Miceli**

Technical Assistant  
e.miceli@ifahsec.org

### **Marie-Hélène Delvaux**

Executive Secretary  
techsec@ifahsec.org

## Communications Department

### **Bernd Halling**

Communications Director  
b.halling@ifahsec.org

### **Myriam Alcain**

Communications Manager  
m.alcain@ifahsec.org

### **Laurence Leclercq**

External Communications Officer  
l.leclercq@ifahsec.org

### **Pamela Barcellona**

Senior Secretary  
p.barcellona@ifahsec.org

## Administration and IT

### **Linda Moortgat**

Administration Manager and IT Coordinator  
l.moortgat@ifahsec.org

# Glossary

<b>3 R's</b>	Refine, reduce and replace
<b>AI</b>	Avian influenza
<b>CAHP</b>	Community Animal Health Policy
<b>CVMP</b>	Committee for Medicinal Products for Veterinary Use
<b>DCP</b>	Decentralised Procedure
<b>DG</b>	Directorate General
<b>EAFN</b>	European Agri-Food Network
<b>EC</b>	European Commission
<b>EFSA</b>	European Food Safety Authority
<b>EISA</b>	European Initiative for Sustainable Development in Agriculture
<b>EMA</b>	European Medicines Agency
<b>EP</b>	European Parliament
<b>EPAA</b>	European Partnership for Alternative Approaches to Animal Testing
<b>EPRUMA</b>	European Platform for the Responsible Use of Medicines in Animals
<b>ETPGAH</b>	European Technology Platform for Global Animal Health
<b>EU</b>	European Union
<b>FAO</b>	Food and Agriculture Organisation
<b>GL</b>	Guideline
<b>GMP</b>	Good Manufacturing Practice
<b>HMA</b>	Heads of Medicines Agencies
<b>IWP</b>	Immunologicals Working Party
<b>MA</b>	Marketing authorisation
<b>MRL</b>	Maximum Residue Limit
<b>MRP</b>	Mutual Recognition Procedure
<b>NGO</b>	Non-Governmental Organisation
<b>OIE</b>	World Organisation for Animal Health
<b>QWP</b>	Quality Working Party
<b>VICH</b>	International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products
<b>WHO</b>	World Health Organisation



# IFAH-Europe

**Representing the European Animal Health Industry**

---

Rue Defacqz, 1  
1000 Brussels  
Belgium

Tel.: +32 (0)2 543 7560  
Fax: +32 (0)2 537 0049

E-mail: [info@ifahsec.org](mailto:info@ifahsec.org)  
[www.ifahaurope.org](http://www.ifahaurope.org)  
May 2007